This is a prospective study on the use of immunoglobulins in the treatment of Guillain-Barré syndrome in four children, three of whom were younger than 3 years of age. All of them were unable to walk and were still deteriorating when the treatment was started. Three patients started recovering within 24 hours, and all the patients were fully mobile within 6 weeks after receiving first dose of immunoglobulins. This report shows the efficacy of intravenous immunoglobulins in the treatment of young children presenting with acute Guillain-Barré syndrome. (J Child Neurol 1994;9:178-180).
Get full access to this article
View all access options for this article.
References
1.
Ropper AH: The Guillain-Barré syndrome. N Engl J Med1992; 336:1130-1136.
2.
Evans OB: Guillain-Barré syndrome in children. Pediatr Rev1986;8:69-74.
3.
Hughes RAC , Newsom-Davis JM, Perkin GD, Pierce JM: Controlled trial of prednisolone in acute polyneuropathy. Lancet1978;2:750-753.
4.
Yoshioka M., Shigekazu K., Hideshige M.: Plasmapheresis in the treatment of the Guillain-Barre syndrome in childhood . Pediatr Neurol1985;1:329-334.
5.
Shahar E., Murphy EG, Roifman CM: Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr1990 ;116:141—144.
6.
Yaklovlev PI, Lecours AR: The myelogenetic cycles of regional maturation of the brain, in Minkowski A (ed): Regional Development of the Brain in Early Life. Oxford, Blackwell, 1967, pp 13-70.
7.
Johnston RB: Immunity, allergy, and diseases of inflammation, in Behrman RE (ed): Nelson Textbook of Pediatrics . Philadelphia, WB Saunders, 1992, pp 545-562.
8.
Asbury AK: Diagnostic consideration in Guillain-Barré syndrome. Ann Neurol1981;9(Suppl): 1—5.
9.
Guillain-Barré Syndrome Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology1984;35:1096-1104.
10.
van der Meche FGA , Schmitz PIM , the Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med1992;17:1123-1129.
11.
Rajah A.: The use of high-dose intravenous immunoglobulins in Guillain-Barré syndrome . Anesthesia1992;17:220-222.
12.
Kleyweg RP, van der Meche FGA, Meultree J.: Treatment of Guillain-Barré syndrome with high dose gammaglobulin . Neurology1988;38:1639-1641.
13.
Urtasun M., Lopez de Munain A., Carrera N., et al: High dose intravenous immunoglobulin in the management of severe Guillain-Barré syndrome. Ann Pharmacother1992;26:32-33.
14.
Castro LHM , Ropper AH: Human immunoglobulin infusion in Guillain-Barré syndrome: Worsening during and after treatment. Neurology1993;43:1034-1036.
15.
Irani DN, Cornblath DR, Chaudhry V., et al: Relapse in Guillain-Barré syndrome after treatment with immunoglobulin . Neurology1993;43:872-875.
16.
Kleyweg RP, van der Meche FGA: Treatment-related fluctuations in Guillain-Barré syndrome after high dose immunoglobulin or plasma-exchange. J Neurol Neurosurg Psychiatry1991; 54:957-960.
17.
Bleck TP: IVIg for GBS: Potential problems in the alphabet soup. Neurology1993;43:857-858.
18.
Koski CL, Gratz E., Sutherland J., Mayer RF: Clinical correlation with anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol1986 ;19:573-577.
19.
Hartung HP, Hughes RAC, Taylor WA, et al: T-cell activation in Guillain-Barré syndrome and in MS: Elevated serum levels of soluble LL-2 receptors. Neurology1990;40:215-218.
20.
Shwartz RS: Overview of the biochemistry and safety of new native intravenous gamma globulin, IGIV, PH 4.25. Am J Med1987 ;88(Suppl 4A):46-51.
